Display options
Cite
Dizdar L, Jünemann LM, Werner TA, et al. Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer. Oncol Lett. 2018;15(3):3779-3789doi: 10.3892/ol.2018.7755.
Dizdar, L., Jünemann, L. M., Werner, T. A., Verde, P. E., Baldus, S. E., Stoecklein, N. H., Knoefel, W. T., & Krieg, A. (2018). Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer. Oncology letters, 15(3), 3779-3789. https://doi.org/10.3892/ol.2018.7755
Dizdar, Levent, et al. "Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer." Oncology letters vol. 15,3 (2018): 3779-3789. doi: https://doi.org/10.3892/ol.2018.7755
Dizdar L, Jünemann LM, Werner TA, Verde PE, Baldus SE, Stoecklein NH, Knoefel WT, Krieg A. Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer. Oncol Lett. 2018 Mar;15(3):3779-3789. doi: 10.3892/ol.2018.7755. Epub 2018 Jan 09. PMID: 29467895; PMCID: PMC5796362.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2018 Mar;15(3):3779-3789. doi: 10.3892/ol.2018.7755. Epub 2018 Jan 09.

Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer.

Oncology letters

Levent Dizdar, Lisa M Jünemann, Thomas A Werner, Pablo E Verde, Stephan E Baldus, Nikolas H Stoecklein, Wolfram T Knoefel, Andreas Krieg

Affiliations

  1. Department of Surgery (A), Heinrich-Heine-University and University Hospital Düsseldorf, D-40225 Düsseldorf, Germany.
  2. Coordination Centre for Clinical Trials, Heinrich-Heine-University and University Hospital Düsseldorf, D-40225 Düsseldorf, Germany.
  3. Institute of Pathology, Cytology and Molecular Pathology, D-51465 Bergisch Gladbach, Germany.

PMID: 29467895 PMCID: PMC5796362 DOI: 10.3892/ol.2018.7755

Abstract

Based on their overexpression and important roles in progression and therapy-resistance in malignant diseases, the inhibitor of apoptosis protein family (IAP) members, survivin and X-linked inhibitor of apoptosis protein (XIAP), represent attractive candidates for targeted therapy. The present study investigated the prognostic and biological relevance of survivin and XIAP in esophageal squamous-cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). Survivin and XIAP expression was analyzed by immunohistochemistry using tissue microarrays containing 120 ESCC and 90 EAC samples as well as the corresponding non-neoplastic esophageal mucosa samples. IAP expression levels were then correlated to clinicopathological parameters and overall survival to identify any associations. In addition, esophageal cancer cell lines were treated with the survivin inhibitor YM155, and the XIAP inhibitors Birinapant and GDC-0152

Keywords: XIAP; YM155; adenocarcinoma; esophageal cancer; squamous-cell carcinoma; survivin

References

  1. J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 - PubMed
  2. Mol Cell. 2007 Jul 6;27(1):17-28 - PubMed
  3. Clin Chim Acta. 2015 Jun 15;446:82-5 - PubMed
  4. Oncogene. 2008 Oct 20;27(48):6276-84 - PubMed
  5. Int J Biochem Mol Biol. 2012;3(2):179-97 - PubMed
  6. Mol Cancer Ther. 2014 Apr;13(4):867-79 - PubMed
  7. Nature. 2000 Dec 21-28;408(6815):1008-12 - PubMed
  8. Semin Cell Dev Biol. 2015 Mar;39:91-6 - PubMed
  9. Nature. 2000 Dec 21-28;408(6815):1004-8 - PubMed
  10. Br J Cancer. 2005 Aug 22;93(4):387-91 - PubMed
  11. Biochem Biophys Res Commun. 2012 Sep 7;425(4):711-6 - PubMed
  12. Clin Cancer Res. 2008 Aug 15;14(16):5000-5 - PubMed
  13. Cancer Biol Ther. 2007 Jun;6(6):973-80 - PubMed
  14. World J Surg Oncol. 2013 Nov 05;11:288 - PubMed
  15. Semin Cell Dev Biol. 2015 Mar;39:132-8 - PubMed
  16. Pharmacol Ther. 2014 Oct;144(1):82-95 - PubMed
  17. Oncogene. 2014 Feb 6;33(6):671-6 - PubMed
  18. Br J Cancer. 2003 Jan 13;88(1):115-9 - PubMed
  19. Br J Cancer. 2016 Feb 16;114(4):427-34 - PubMed
  20. Pathologe. 1987 May;8(3):138-40 - PubMed
  21. Oncol Rep. 2005 Jun;13(6):1241-6 - PubMed
  22. Med Oncol. 2012 Dec;29(5):3009-16 - PubMed
  23. Eur J Cancer. 2007 Jun;43(9):1445-51 - PubMed
  24. Cell. 2000 Sep 1;102(5):545-8 - PubMed
  25. Dis Esophagus. 2009;22(5):402-8 - PubMed
  26. PLoS One. 2013 Nov 04;8(11):e78343 - PubMed
  27. Cancer. 1992 Jan 15;69(2):277-84 - PubMed
  28. Cell Death Dis. 2013 Aug 29;4:e782 - PubMed
  29. Oncotarget. 2017 Jan 31;8(5):8369-8382 - PubMed
  30. Cancer Res. 1993 Sep 1;53(17):3976-85 - PubMed
  31. Tumour Biol. 2011 Dec;32(6):1147-53 - PubMed
  32. Clin Cancer Res. 2004 Jun 1;10(11):3737-44 - PubMed
  33. Exp Mol Pathol. 2004 Jun;76(3):253-9 - PubMed
  34. Am J Gastroenterol. 2008 Nov;103(11):2694-9 - PubMed
  35. Cancer Cell. 2010 Jan 19;17(1):53-64 - PubMed
  36. Cell. 2000 Jul 7;102(1):33-42 - PubMed
  37. J Clin Invest. 2004 Oct;114(8):1117-27 - PubMed
  38. Pharmacol Res. 2016 Nov;113(Pt A):236-244 - PubMed
  39. Eur J Cardiothorac Surg. 2010 Feb;37(2):440-5 - PubMed
  40. Prostaglandins Other Lipid Mediat. 2011 Feb;94(1-2):25-33 - PubMed
  41. Nat Rev Drug Discov. 2012 Feb 01;11(2):109-24 - PubMed
  42. Gastroenterol Clin North Am. 2009 Mar;38(1):17-25, vii - PubMed
  43. PLoS One. 2014 Feb 14;9(2):e88713 - PubMed
  44. Int J Cancer. 2006 Oct 1;119(7):1717-22 - PubMed
  45. Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11936-41 - PubMed
  46. Lancet. 2013 Feb 2;381(9864):400-12 - PubMed
  47. J Med Chem. 2012 May 10;55(9):4101-13 - PubMed
  48. Oncotarget. 2015 Jul 30;6(21):18445-59 - PubMed
  49. Cancer. 2003 Apr 1;97(7):1616-23 - PubMed
  50. Dis Esophagus. 2006;19(5):355-9 - PubMed
  51. J Am Coll Surg. 2004 Feb;198(2):205-11 - PubMed
  52. Folia Histochem Cytobiol. 2004;42(3):169-72 - PubMed
  53. J Hematol Oncol. 2014 Aug 20;7:62 - PubMed
  54. Med J Aust. 2009 Sep 21;191(6):310-4 - PubMed
  55. J Biol Chem. 2004 Aug 13;279(33):34087-90 - PubMed

Publication Types